Weight loss drugs like Ozempic deliver more health benefits than expected.

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Blockbuster GLP-1 medications are changing patient care, impacting surgery volumes and reshaping the financial landscape of the healthcare industry.

G LP-1 drugs containing semaglutide (the active ingredient in Ozempic and Wegovy) have exploded in popularity for their ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...